A new review proposes that declining estradiol during the menopause transition may weaken cardiovascular mitochondria by ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
FOURLIGHT-1 shows atirmociclib plus fulvestrant improved PFS to 9.4 vs 6.6 months after prior CDK4/6 inhibition in HR+/HER2− ...
Faeth Therapeutics announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled ?Characterising the efficacy of ...
These data lend support for Faeth’s multi-node strategy, with two upcoming readouts: FTH-PIK-201 topline data in second-line advanced endometrial cancer by year-end 2026 and FTH-PIK-101 interim data ...
UCLA investigators have developed a new artificial intelligence-based platform that could help scientists identify promising drug combinations to overcome treatment resistance in cancer.
Combining EP300 degradation with AKT inhibition slowed osteosarcoma growth and prolonged survival in preclinical mouse models ...
A natural compound extracted from a medicinal plant has shown surprising promise against rheumatoid arthritis. In rats, it ...
A 2026 review finds that epigenetic changes sustain PI3K/AKT signaling in hepatocellular carcinoma, while experimental ...
Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September ...
BridgeBio Oncology's total equity value of $226 million is lower than its liquid assets of $344.1 million as of June 30. See ...
Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer; Poster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results